CD33 and cancer: For example, Mylotarg® (gemtuzumab) is a currently FDA-approved monoclonal antibody against CD33 for the selective delivery of small molecule chemotherapeutics to acute myeloid leukemia (AML) cancer cells that overexpress CD33 [104].